Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis.
Harbo HF, Lie BA, Sawcer S, Celius EG, Dai KZ, Oturai A, Hillert J, Lorentzen AR, Laaksonen M, Myhr KM, Ryder LP, Fredrikson S, Nyland H, Sørensen PS, Sandberg-Wollheim M, Andersen O, Svejgaard A, Edland A, Mellgren SI, Compston A, Vartdal F, Spurkland A. Harbo HF, et al. Among authors: edland a. Tissue Antigens. 2004 Mar;63(3):237-47. doi: 10.1111/j.0001-2815.2004.00173.x. Tissue Antigens. 2004. PMID: 14989713
Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.
Myhr KM, Riise T, Green Lilleås FE, Beiske TG, Celius EG, Edland A, Jensen D, Larsen JP, Nilsen R, Nortvedt MW, Smievoll AI, Vedeler C, Nyland HI. Myhr KM, et al. Among authors: edland a. Neurology. 1999 Mar 23;52(5):1049-56. doi: 10.1212/wnl.52.5.1049. Neurology. 1999. PMID: 10102427 Clinical Trial.
Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis.
Wesnes K, Myhr KM, Riise T, Kvistad SS, Torkildsen Ø, Wergeland S, Holmøy T, Midgard R, Bru A, Edland A, Eikeland R, Gosal S, Harbo HF, Kleveland G, Sørenes YS, Øksendal N, Bjørnevik K. Wesnes K, et al. Among authors: edland a. Mult Scler Relat Disord. 2021 May;50:102801. doi: 10.1016/j.msard.2021.102801. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33636616 Free article. Clinical Trial.
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis.
Lie IA, Wesnes K, Kvistad SS, Brouwer I, Wergeland S, Holmøy T, Midgard R, Bru A, Edland A, Eikeland R, Gosal S, Harbo HF, Kleveland G, Sørenes YS, Øksendal N, Barkhof F, Vrenken H, Myhr KM, Bø L, Torkildsen Ø. Lie IA, et al. Among authors: edland a. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 23;9(5):e200008. doi: 10.1212/NXI.0000000000200008. Print 2022 Sep. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35738901 Free PMC article.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators. Sorensen PS, et al. Among authors: edland a. Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2. Lancet Neurol. 2011. PMID: 21742556 Clinical Trial.
25 results